B7-H3 was Highly Expressed in Human Primary Hepatocellular Carcinoma and Promoted Tumor Progression

Wang, Feifei; Wang, Guoyan; Liu, Tongshen; Yu, Guohua; Zhang, Guangbo; Luan, Xiying

doi:10.3109/07357907.2014.909826

Cited by 44 publications

(46 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although our previous findings (10) revealed an association between tumor tissue B7-H3 levels and clinicopathological characteristics, the present study identified no significant association between sB7-H3 levels and certain clinicopathological characteristics, including age, sex and lymph node metastasis. However, sB7-H3 levels were found to differ significantly among the clinical stages examined, and were associated with distant metastasis.…”

Section: Association Between Sb7-h3 Il-17 Il-8 and Il-6 Levels In Hcontrasting

confidence: 99%

“…However, neither of these are highly specific markers for liver cancer (27), and therefore, the attention of numerous researchers has turned toward finding a more specific diagnostic marker for liver cancer. Previously, we reported that B7-H3 levels were increased in the tumor tissue of HCC patients (10). In the present study, this investigation was extended to include serum levels of sB7-H3 and the cytokines IL-17, IL-8 and IL-6 in HCC patients, and the potential of combining these factors for use as diagnostic biomarkers of HCC was evaluated.…”

Section: Discussionmentioning

confidence: 89%

“…Given our previous findings that B7-H3 was highly expressed in tumor tissue (10), and the results of the present study demonstrating increased serum levels of sB7-H3 and a positive correlation between serum sB7-H3 and IL-17 levels in HCC patients, efforts were directed toward assessing the accuracy of using sB7-H3, IL-17, IL-8 and IL-6 in HCC diagnosis using ROC analysis. The potential value of using sB7-H3, IL-17, IL-8 and IL-6 in HCC diagnosis was also evaluated using logistic regression analysis.…”

Section: Discussionmentioning

confidence: 97%

“…This sB7-H3 is involved in the regulation of immune responses and autoimmune diseases, but its role in the regulation of T-cell responses remains controversial (9). Our previous study revealed that the cancer tissue from hepatocellular carcinoma (HCC) patients exhibited significantly increased levels of B7-H3 (10). B7-H3 has also been reported to be involved in the development of a variety of other solid tumor tissue cancer types, including osteosarcoma, pancreatic cancer, glioma, bladder cancer and non-small cell lung cancer (11)(12)(13)(14)(15), as well as in the development of inflammatory diseases (16).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Involvement of soluble B7‑H3 in combination with the serum inflammatory cytokines interleukin‑17, ‑8 and ‑6 in the diagnosis of hepatocellular carcinoma

Wang

et al. 2017

Oncol Lett

Self Cite

View full text Add to dashboard Cite

Abstract. Previous studies have demonstrated that B7-H3, and the inflammatory cytokines interleukin (IL)-17, IL-8 and IL-6, are involved in the development of a variety of tumors. The objectives of the present study were: i) To investigate the association between soluble B7-H3 (sB7-H3) and cytokine levels of IL-17, IL-8 and IL-6 in the serum of patients with hepatocellular carcinoma (HCC); and ii) to determine their potential value for use in HCC diagnosis. Serum sB7-H3, IL-17, IL-8 and IL-6 levels in the HCC patients and healthy control subjects were measured using ELISA. The accuracy of each of these biomarkers in HCC diagnosis was compared using a receiver operating characteristic curve and the area under the curve (AUC). A logistic regression model was used to investigate the accuracy of diagnosing HCC when evaluated using combined determinations of sB7-H3, IL-17, IL-8 and IL-6 levels. The data demonstrated that serum levels of sB7-H3, IL-17, IL-8 and IL-6 were significantly increased in HCC patients compared with those in the healthy control group. Serum sB7-H3 levels were positively associated with serum IL-17, whereas serum IL-8 levels were negatively correlated with serum IL-17 levels. The AUC values for sB7-H3, IL-17, IL-8 and IL-6 were 83.2, 65.7, 95.3 and 97.0%, respectively, and indicated that all four biomarkers exhibited a statistically significant capacity for diagnosing HCC. Using the logistic regression model, the AUC value, sensitivity and specificity, as determined for the combination of the four biomarkers, were 99.2, 96.67 and 97.14%, respectively. This was significantly greater than that achieved when any single biomarker was used alone in the logistic regression model to assess their accuracy in HCC diagnosis. The optimum cutoff value of the predicted probability obtained by the combination of sB7-H3, IL-17, IL-8 and IL-6 in the regression model was 0.5745. To conclude, the present study revealed that there exists a positive association between serum sB7-H3 and IL-17 levels in HCC patients. Determinations involving the combination of serum sB7-H3, IL-17, IL-8 and IL-6 levels demonstrate great potential for use in HCC diagnosis.

show abstract

Section: Association Between Sb7-h3 Il-17 Il-8 and Il-6 Levels In Hcontrasting

confidence: 99%

Section: Discussionmentioning

confidence: 89%

Section: Discussionmentioning

confidence: 97%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Involvement of soluble B7‑H3 in combination with the serum inflammatory cytokines interleukin‑17, ‑8 and ‑6 in the diagnosis of hepatocellular carcinoma

Wang

et al. 2017

Oncol Lett

Self Cite

View full text Add to dashboard Cite

show abstract

“…The precise functions of CD276 in tumor immunity are complicated as both T cell co-stimulatory and co-inhibitory effects have been reported [13]. Recently, emerging studies reveal that high tumor CD276 expression is correlated with more advanced disease and poor prognosis [9, 14, 15]. And CD276 also affects tumor progression and chemosensitivity by regulating oncogenic signaling pathways activated in non-immunological systems [16, 17].…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-187 inhibits tumor growth and invasion by directly targeting CD276 in colorectal cancer

et al. 2016

View full text Add to dashboard Cite

Aberrantly expressed microRNAs contribute to the initiation and progression of human cancers. However, the underlying functions of microRNA-187 (miR-187) in colorectal cancer (CRC) remain largely unexplored. Here, we demonstrated that miR-187 was significantly down-regulated in CRC tissues and cell lines compared to their normal counterparts. By Kaplan-Meier analysis, we revealed that decreased miR-187 expression was closely associated with shorter overall survival and relapse-free survival of patients with CRC. By gain- and loss-of-function studies, we showed that miR-187 remarkably suppressed CRC cell proliferation, migration, invasion, and promoted cell apoptosis. Furthermore, bioinformatics analysis and luciferase reporter assay identified that CD276 was the direct functional target of miR-187 in CRC. Genetic silencing of CD276 recapitulated similar phenotype as observed in over-expression of miR-187, and restoration of CD276 completely rescued the inhibitory effect of miR-187 in CRC cells. Taken together, our study implied the essential roles of miR-187 in suppressing CRC progression, and a novel link between miR-187 and CD276 in CRC.

show abstract

Targeting immunotherapy for bladder cancer using anti‐CD3× B7‐H3 bispecific antibody

et al. 2018

Cancer Medicine

View full text Add to dashboard Cite

ObjectiveB7‐H3 is attractive for cancer immunotherapy with B7‐H3 overexpressed tumors. To explore whether B7‐H3 is an effective target for patients with bladder cancer, anti‐CD3× anti‐B7‐H3 bispecific antibodies (B7‐H3Bi‐Ab) was armed with activated T cells (ATC) to kill bladder cancer cells.MethodsHigh expressions of B7‐H3 on human bladder cancer cells were detected, including Pumc‐91 and T24 cells, and their chemotherapeutic drug‐resistant counterparts. ATC generated from healthy donors were stimulated with anti‐CD3 monoclonal antibody and interleukin‐2 (IL‐2) for 13 days. The ability of ATC armed with B7‐H3Bi‐Ab to kill bladder cancer cells was detected by flow cytometry, LDH, Elisa, and luciferase quantitative assay. Moreover, ATC generated from bladder cancer patients was armed with B7‐H3Bi‐Ab to verity the cell killing by the methods as previously described.ResultsCompared with unarmed ATC, a significant increased cytotoxicity of B7‐H3Bi‐Ab‐armed ATC against bladder cancer cells was discovered. The B7‐H3Bi‐Ab‐armed ATC secreted more IFN‐γ, TNF‐α, and expressed high levels of activation marker CD69. Interestingly, despite the presence of immunosuppression in patients and resistance in chemotherapeutic drug‐resistant cancer cell lines, B7‐H3Bi‐Ab‐armed ATC from patients with bladder cancer still showed significant cytotoxic activity against bladder cancer cells and their chemotherapeutic drug‐resistant counterparts.ConclusionB7‐H3 is an effective target for bladder cancer. B7‐H3Bi‐Ab enhances the ability of ATC to kill bladder cancer cells. B7‐H3Bi‐Ab‐armed ATC is promisingly to provide a novel strategy for current bladder cancer therapy.

show abstract

B7-H3 was Highly Expressed in Human Primary Hepatocellular Carcinoma and Promoted Tumor Progression

Cited by 44 publications

References 30 publications

Involvement of soluble B7‑H3 in combination with the serum inflammatory cytokines interleukin‑17, ‑8 and ‑6 in the diagnosis of hepatocellular carcinoma

Involvement of soluble B7‑H3 in combination with the serum inflammatory cytokines interleukin‑17, ‑8 and ‑6 in the diagnosis of hepatocellular carcinoma

MicroRNA-187 inhibits tumor growth and invasion by directly targeting CD276 in colorectal cancer

Targeting immunotherapy for bladder cancer using anti‐CD3× B7‐H3 bispecific antibody

Contact Info

Product

Resources

About